Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma

INTRODUCTION: Since the July 2017 National Comprehensive Cancer Network (NCCN) malignant pleural mesothelioma (MPM) guideline revision recommended second-line immune checkpoint inhibitors (ICIs), studies have suggested a greater response to ICI among patients with nonepithelioid MPM. Nevertheless, l...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Roger Y., Mitra, Nandita, Bagley, Stephen J., Marmarelis, Melina E., Haas, Andrew R., Rendle, Katharine A., Vachani, Anil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474474/
https://www.ncbi.nlm.nih.gov/pubmed/34590032
http://dx.doi.org/10.1016/j.jtocrr.2021.100188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474474/
https://www.ncbi.nlm.nih.gov/pubmed/34590032
http://dx.doi.org/10.1016/j.jtocrr.2021.100188

Ejemplares similares